---
figid: PMC2001220__10549_2007_9697_Fig1_HTML
figtitle: Cross-talk between signal transduction pathways and ER signaling in endocrine
  resistant breast cancer, with opportunities for targeted intervention
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC2001220
filename: 10549_2007_9697_Fig1_HTML.jpg
figlink: /pmc/articles/PMC2001220/figure/Fig1/
number: F1
caption: Cross-talk between signal transduction pathways and ER signaling in endocrine
  resistant breast cancer, with opportunities for targeted intervention. Estrogen
  (E2)-liganded ER activates E2-regulated genes in classical pathway (thick black
  arrow), but following long-term tamoxifen therapy resistance can develop with bidirectional
  cross-talk (gray arrows) between ER and growth factor receptors, with association
  of membrane bound ER with growth factor receptors, and/or IGFR or EGFR/HER2 activation
  of ER phosphorylation. Stars show various targeted therapies. AI aromatase inhibitor,
  SERD selective estrogen receptor down-regulator, MoAb monoclonal antibodies, TKI
  tyrosine kinase inhibitor, FTI farnesyltransferase inhibitor, CCI cell cycle inhibitor.
  Reprinted from [] with permission from the American Association for Cancer Research
papertitle: 'FemaraÂ® and the future: tailoring treatment and combination therapies
  with Femara.'
reftext: Matthew Ellis, et al. Breast Cancer Res Treat. 2007 Oct;105(Suppl 1):105-115.
year: '2007'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9683514
figid_alias: PMC2001220__F1
figtype: Figure
redirect_from: /figures/PMC2001220__F1
ndex: 02410ac0-dec2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2001220__10549_2007_9697_Fig1_HTML.html
  '@type': Dataset
  description: Cross-talk between signal transduction pathways and ER signaling in
    endocrine resistant breast cancer, with opportunities for targeted intervention.
    Estrogen (E2)-liganded ER activates E2-regulated genes in classical pathway (thick
    black arrow), but following long-term tamoxifen therapy resistance can develop
    with bidirectional cross-talk (gray arrows) between ER and growth factor receptors,
    with association of membrane bound ER with growth factor receptors, and/or IGFR
    or EGFR/HER2 activation of ER phosphorylation. Stars show various targeted therapies.
    AI aromatase inhibitor, SERD selective estrogen receptor down-regulator, MoAb
    monoclonal antibodies, TKI tyrosine kinase inhibitor, FTI farnesyltransferase
    inhibitor, CCI cell cycle inhibitor. Reprinted from [] with permission from the
    American Association for Cancer Research
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erbb2
  - Egfr
  - ras
  - Hras
  - Kras
  - Rem1
  - Lrpap1
  - Rptor
  - Pik3r1
  - Akt1
  - Mdk
  - Rps6ka1
  - Rps6ka2
  - Mybbp1a
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - IGF1R
  - ERBB2
  - EGFR
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - LRPAP1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MSH6
  - MYBBP1A
  - PELP1
  - Sos
  - Ras64B
  - Ras85D
  - Rap1
  - fzr
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Dsor1
  - Mtk
  - MKP-4
  - p38b
  - rl
  - Dap160
  - MED14
  - pzg
  - Estrogen
  - Tamoxifen
  - Cancer
  - Lung cancer
  - Noonan syndrome
---
